贝派地酸用于二级预防
Bempedoic Acid in Secondary Prevention.
作者信息
Mousavi Idine, Nambi Vijay, Abushamat Layla A, Al-Kindi Sadeer G, Shapiro Michael D, Sperling Laurence, Virani Salim S, Minhas Abdul Mannan Khan
机构信息
Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
Division of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
出版信息
Am J Prev Cardiol. 2024 Aug 6;19:100715. doi: 10.1016/j.ajpc.2024.100715. eCollection 2024 Sep.
•Bempedoic acid has been shown to reduce major adverse cardiovascular outcomes in patients unable to take statins due to statin-associated side effects.•Analysis of CLEAR Outcomes trial data reveals possible differences in baseline characteristics between the primary and secondary prevention subgroups.•Further research is needed to optimize use of bempedoic acid and clarify its impact on cardiovascular outcomes in diverse patient populations.
•已证明贝派地酸可降低因他汀类药物相关副作用而无法服用他汀类药物的患者的主要不良心血管事件。
•对CLEAR Outcomes试验数据的分析显示，一级预防亚组和二级预防亚组之间的基线特征可能存在差异。
•需要进一步研究以优化贝派地酸的使用，并阐明其对不同患者群体心血管结局的影响。
Zotero 插件